FDA Clears Insera’s CLEAR Aspiration System, Which Pulses Suction to Remove Peripheral Clots

Photo: Piron Guillaume / Unsplash

The 510(k) clearance covers fresh, soft clots in peripheral arteries and veins and rests on bench and animal testing, not on clinical outcome data.

Background

Aspiration thrombectomy is a familiar tool in interventional radiology: a catheter is advanced to a clot, suction is applied, and the material is drawn out. Most systems hold that vacuum steady. Insera Therapeutics, a Dallas-based device company, has built its product around a different idea it calls cyclical aspiration, in which the suction pulses instead of holding constant [1][3].

According to a 2019 company release, the system lets operators change both the level of vacuum and the timing of suction within a set range [5]. The same release cited research associating cyclical suction with more complete clot ingestion than static suction, but it was a company announcement, not a peer-reviewed comparison [5]. The CLEAR system already carries a CE Mark in Europe. Its 2019 European approval covered clot aspiration in acute ischemic stroke and cerebral venous sinus thrombosis, along with separate approvals for other uses [5].

What the FDA Cleared

The FDA's 510(k) database lists submission K253404 for the CLEAR Aspiration System from Insera Therapeutics. The agency received it on Sept. 30, 2025, and issued a decision of "substantially equivalent" on June 24, 2026, after a traditional review by its cardiovascular panel [1]. Insera announced the clearance publicly on Sept. 28, 2026 [3]. A news report from Endovascular Today followed on Nov. 12 [4].

The cleared indication is narrow. The system is cleared to remove fresh, soft emboli and thrombi from peripheral arterial and venous vessels [2][3]. The FDA indication covers peripheral vessels only and does not include the stroke uses approved in Europe [2][4].

The 510(k) summary describes four parts: a non-sterile pump, a single-use canister with intermediate tubing, sterile aspiration tubing and a sterile over-the-wire catheter. Cyclical, Uniform and Saver suction presets are available [2]. The company describes the Saver setting as a "blood saver" mode [3]. The device falls under 21 CFR 870.5150 with product code QEZ, classified as peripheral mechanical thrombectomy with aspiration [2].

Insera's primary predicate was the Penumbra Indigo Aspiration System (K142870). Two other Penumbra Indigo clearances were listed as reference devices [2]. In other words, the CLEAR system reached the US market by being compared with the device it will be competing against.

What 510(k) Clearance Does and Doesn't Mean

A 510(k) is not a premarket approval. The FDA finds a device substantially equivalent when it has the same intended use as a legally marketed predicate. It must also have either the same technological characteristics or different ones that do not raise different questions of safety and effectiveness [6]. The submission must show the device is as safe and effective as the predicate, which is not the same as showing it is better [6]. Performance data in a 510(k) can be clinical, but the FDA's own description lists bench, sterility, electromagnetic compatibility, software and biocompatibility testing as typical examples [6].

In this case, the 510(k) summary states that no clinical data were used. The clearance rested on bench and design verification testing, durability and usability testing against the predicate, standards testing for electrical safety and EMC, sterilization and shelf-life testing, software and cybersecurity validation, biocompatibility, and an animal study [2]. The animal study found an in-vivo safety profile similar to the predicate's at acute and chronic time points [2]. Insera's chief medical officer, Vallabh Janardhan, MD, described the same package of testing, including GLP animal studies [3].

So the clearance establishes that the FDA considers CLEAR comparable to Indigo for peripheral clot removal. It does not show that pulsed suction removes more clot, saves more blood or improves patient outcomes in people. Those claims would need clinical studies, and the company has not reported any as part of this clearance [2][4].

Physicians quoted in the release were enthusiastic. Mahmood Razavi, MD, of St. Joseph Heart & Vascular Center called it "leading-edge technology" for peripheral thrombectomy [3]. Endovascular Today noted that the announcement presented no clinical data, only physician endorsements [4]. Chief executive Vikram Janardhan said the company has 108 patent filings, 100 of them issued or allowed [3].

What Comes Next

The release gives no date for a US commercial launch, no pricing and no plans for a clinical trial [3][4]. The questions that matter to interventionalists are clinical ones. Does cyclical suction clear peripheral clot faster or more completely than steady suction, does it reduce blood loss, and does it change outcomes such as limb salvage or symptom relief? The 510(k) does not answer those. Head-to-head clinical data, ideally independent, would.

Insera's European stroke indication also means US readers may hear about neurovascular use. That use is not part of this clearance [2][5].

This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician.

References

  1. US Food and Drug Administration. 510(k) Premarket Notification: K253404, CLEAR Aspiration System (Insera Therapeutics, Inc.). Decision date June 24, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K253404

  2. US Food and Drug Administration. 510(k) Summary, K253404, CLEAR Aspiration System. June 24, 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf25/K253404.pdf

  3. Insera Therapeutics, Inc. Insera Therapeutics, Inc. Receives U.S. FDA 510(k) Clearance for the CLEAR Aspiration System Featuring Cyclical Aspiration (press release). BioSpace. Sept. 28, 2026. https://www.biospace.com/press-releases/insera-therapeutics-inc-receives-u-s-fda-510k-clearance-for-the-clear-aspiration-system-featuring-cyclical-aspiration

  4. Endovascular Today. Insera's Clear Aspiration System Cleared by FDA. Nov. 12, 2026. https://evtoday.com/news/inseras-clear-aspiration-system-cleared-by-fda

  5. Insera Therapeutics. Insera Earns CE Mark Approval for Cyclical-suction Stroke Thrombectomy Platform, the CLEAR Aspiration System (press release). BioSpace. April 8, 2019. https://www.biospace.com/insera-earns-ce-mark-approval-for-cyclical-suction-stroke-thrombectomy-platform-the-clear-aspiration-system

  6. US Food and Drug Administration. Premarket Notification 510(k). https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k

Phillip Leblanc

What I cover

I write wellness and medical culture pieces for The Culture Desk RX: strangers sweating it out in a street sauna, doctors with unusual side hustles, and the general human comedy of trying to stay healthy. A good fraud story and a good sauna story have more in common than you’d think. Somebody’s always sweating.

I’ve seen everything from kickbacks dressed up as “consulting fees” to charities that are generous mostly to their own founders. If a dollar goes missing between the patient and the provider, I find it.

I focus on interventional radiology and the quiet evolution of robotic systems that are breaking medical ceilings, healing patients with catheters instead of scalpels. I believe in the good guys, so I write about altruistic causes: the nurses, doctors and nonprofits doing honest work with no PR team.

My Background

Growing up in East Durham, North Carolina, you learn two things: how to throw a jab and when to keep your mouth closed. My editor says it explains my interviewing style.

Journalistic Ethics

Vital Biomedical News is reader-funded and beholden to no one. We take no money from pharmaceutical or medical device companies, and neither do I. I don’t accept gifts, junkets or favors, and I don’t bankroll political causes. My only allegiance is to the paper trail.

I deal in documents, not anecdotes. Every claim is corroborated against primary sources: court filings, federal records, clinical data and the people who were actually in the room. Sources get candor, confidential sources get anonymity, and powerful institutions get scrutiny, whether they welcome it or not.

I’m unfailingly courteous to everyone I interview, including the people I’m investigating. Civility is not clemency.

Previous
Previous

Jacksonville Pharmacy Owner and Accountant Indicted in Alleged $51 Million HIV PEP Billing Scheme

Next
Next

Spa Company's Testing Arm, Backed by a Trump-Linked Fund, Wins Nearly $40 Million in Ebola Contracts